1.
American Cancer Society. Cancer facts and figures 2015. Atlanta: American Cancer Society; 2015.
2.
Zhang TY, Agarwal N, Sonpavde G, DiLorenzo G, Bellmunt J, Vogelzang NJ. Management of castrate resistant prostate cancer—recent advances and optimal sequence of treatments. Curr Urol Rep. 2013;14:174–83.
CrossRefPubMed
3.
Yap TA, Pezaro CJ, de Bono JS. Cabazitaxel in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2012;12(9):1129–36.
CrossRefPubMed
4.
Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol. 2006;175(1):27–34.
CrossRefPubMed
5.
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20. PubMedPMID: 15470214.
6.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.
CrossRefPubMed
7.
Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756–64.
PubMed
8.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.
CrossRefPubMed
9.
Vrignaud P, Semiond D, Benning V, Beys E, Bouchard H, Gupta S. Preclinical profile of cabazitaxel. Drug Des Devel Ther. 2014;13(8):1851–67.
CrossRef
10.
Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15(2):723–30.
CrossRefPubMed
11.
Diéras V, Lortholary A, Laurence V, Delva R, Girre V, Livartowski A, et al. Cabazitaxel in patients with advanced solid tumors: results of a phase I and pharmacokinetic study. Eur J Cancer. 2013;49(1):25–34.
CrossRefPubMed
12.
Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol. 2005;32(6 Suppl 7):S3–8.
CrossRefPubMed
13.
Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun. 2014;25(5):5548.
CrossRef
14.
Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res. 2013;19(11):2973–83.
CrossRefPubMed
15.
Bourre L, Nicolle D, Legrier M-E, Yvonnet V, Charpentier J, Poupon M-F, et al. Evaluation of the response to cabazitaxel of a docetaxel-responsive hormone-refractory prostate tumor xenograft model (HID28). In: American Society of Clinical Oncology Annual Meeting. Chicago, Illinois; June 1–5, 2012. Abstract e15161.
16.
Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of taxol resistance related to microtubules. Oncogene. 2003;22(47):7280–95. Review. PubMed PMID: 14576838.
17.
Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277(5698):665–7.
CrossRefPubMed
18.
Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;(15):55–61. Review. PubMed PMID: 7912530.
19.
Blagosklonny MV. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle. 2007;6(1):70–4. Epub 2007 Jan 9. Review. PubMed PMID: 17245109.
20.
Lanzi C, Cassinelli G, Cuccuru G, Supino R, Zuco V, Ferlini C, et al. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate. 2001;48(4):254–64.
CrossRefPubMed
21.
McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785(2):96–132. Epub 2007 Nov 12. Review. PubMed PMID: 18068131.
22.
Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316–23. Review. PubMed PMID: 15549093.
23.
de Leeuw R, Berman-Booty LD, Schiewer MJ, Ciment SJ, Den RB, Dicker AP, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015;21(4):795–807.
CrossRefPubMedPubMedCentral
24.
Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 2009;69(21):8386–94.
CrossRefPubMedPubMedCentral
25.
Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71(18):6019–29.
CrossRefPubMedPubMedCentral
26.
van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer. 2013;49(18):3821–30.
CrossRefPubMed
27.
Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. 2014. [Epub ahead of print] PubMed PMID: 24837187.
28.
van Soest RJ, de Morrée ES, Kweldam CF, de Ridder CM, Wiemer EA, Mathijssen RH, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, castration-resistant prostate cancer. Eur Urol. 2015;67(6):981–5.
CrossRefPubMed
29.
Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, et al. Mechanisms of resistance to cabazitaxel. Mol Cancer Ther. 2015;14(1):193–201.
CrossRefPubMedPubMedCentral
30.
Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005;116(5):824–9.
CrossRefPubMed
31.
Ikui AE, Yang CP, Matsumoto T, Horwitz SB. Low concentrations of taxol cause mitotic delay followed by premature dissociation of p55CDC from Mad2 and BubR1 and abrogation of the spindle checkpoint, leading to aneuploidy. Cell Cycle. 2005;4(10):1385–8 Epub 2005 Oct 28.
CrossRefPubMed
32.
Hernández-Vargas H, Palacios J, Moreno-Bueno G. Telling cells how to die: docetaxel therapy in cancer cell lines. Cell Cycle. 2007;6(7):780–3. Epub 2007 Apr 22. Review. PubMed PMID: 17377494.
33.
Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, et al. Chromosomal instability determines taxane response. Proc Natl Acad Sci USA. 2009;106(21):8671–6 Epub 2009 May 19.
CrossRefPubMedPubMedCentral
34.
Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet. 2005;44(4):349–66. Review. PubMed PMID: 15828850.
35.
Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10(3):194–204. Epub 2010 Feb 11. Review. Erratum in: Nat Rev Cancer. 2010;10(4):309. PubMed PMID: 20147901.
36.
Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer. 1998;77(4):562–6.
CrossRefPubMedPubMedCentral
37.
Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci. 2002;59(7):1198–211.
CrossRefPubMed
38.
Hara T, Ushio K, Nishiwaki M, Kouno J, Araki H, Hikichi Y, et al. A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line. Cell Biol Int. 2010;34(2):177–84.
CrossRefPubMed
39.
Monzó M, Rosell R, Sánchez JJ, Lee JS, O’Brate A, González-Larriba JL, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 1999;17(6):1786–93.
PubMed
40.
Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011;19(5):664–78. Erratum in: Cancer Cell. 2013;23(4):557. PubMed PMID: 21575865.
41.
Sung M, Giannakakou P. BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene. 2014;33(11):1418–28 Epub 2013 Mar 25.
CrossRefPubMedPubMedCentral
42.
Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 2007;13(24):7413–20.
CrossRefPubMed
43.
Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115(2):359–63 Epub 2008 Jul 23.
CrossRefPubMed
44.
Font A, Taron M, Gago JL, Costa C, Sánchez JJ, Carrato C, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol. 2011;22(1):139–44 Epub 2010 Jul 5.
CrossRefPubMed
45.
Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, et al. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer. 2011;104(2):316–23 Epub 2010 Dec 14.
CrossRefPubMedPubMedCentral
46.
Gallagher DJ, Cronin AM, Milowsky MI, Morris MJ, Bhatia J, Scardino PT, et al. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU Int. 2012;109(5):713–9 Epub 2011 Jul 14.
CrossRefPubMedPubMedCentral
47.
Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell. 2007;11(6):498–512.
CrossRefPubMed
48.
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28.
CrossRefPubMed
49.
Gan Y, Wientjes MG, Au JL. Relationship between paclitaxel activity and pathobiology of human solid tumors. Clin Cancer Res. 1998;4(12):2949–55.
PubMed
50.
Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, et al. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate. 2013;73(4):418–27 Epub 2012 Sep 19.
CrossRefPubMedPubMedCentral
51.
Burkhart DL, Sage J. Cellular mechanisms of tumor suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8(9):671–82. Review. PubMed PMID: 18650841.
52.
Russo AJ, Magro PG, Hu Z, Li WW, Peters R, Mandola J, et al. E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res. 2006;66(14):7253–60.
CrossRefPubMed
53.
Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, et al. Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res. 2009;7(2):210–20 Epub 2009 Feb 10.
CrossRefPubMedPubMedCentral
54.
Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM, et al. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res. 2007;67(13):6192–203.
CrossRefPubMedPubMedCentral
55.
Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2014;20(4):890–903 Epub 2013 Dec 9.
CrossRefPubMedPubMedCentral
56.
Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res. 2012;72(18):4611–5.
CrossRefPubMedPubMedCentral
57.
Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, et al. Antitumor activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23(11):2943–7.
CrossRefPubMed
58.
Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, et al. Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series. Clin Genitourin Cancer. 2015;13(3):193–8. Epub 2014 Nov 7. Review. PubMed PMID: 25466676.
59.
Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014;74(8):2270–82.
CrossRefPubMedPubMedCentral
60.
Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1(5):582–91.
CrossRefPubMed
61.
Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol. 2015. pii: mdv282. [Epub ahead of print] PubMed PMID: 26117829.
62.
Fulda S, Debatin K-M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25(34):4798–811.
CrossRefPubMed
63.
Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer. 2012;118(24):6063–71 Epub 2012 Jun 6.
CrossRefPubMedPubMedCentral
64.
Rescigno P, Lorente D, Bianchini D, Kolinsky M, Zafeiriou Z, Ferraldeschi R, et al. Impact of PTEN protein loss on response to docetaxel and overall survival (OS) in metastatic castration resistant ptostate cancer (mCRPC) patients. In European Society of Medical Oncology Conference Proceedings; 2015.
65.
Liu Z, Zhu G, Getzenberg RH, Veltri RW. The upregulation of PI3 K/Akt and MAP kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer. J Cell Biochem. 2015;116(7):1341–9.
CrossRefPubMed
66.
Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJJ. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther. 2008;7(9):2649–61.
CrossRefPubMed
67.
Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZ, He LY. Silencing notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax. Oncol Lett. 2012;3(4):879–84.
PubMedPubMedCentral
68.
Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012;22(3):373–88.
CrossRefPubMed
69.
Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M, et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 2014;9(1):75–89 Epub 2014 Sep 25.
CrossRefPubMed
70.
Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res. 2006;12(18):5578–86.
CrossRefPubMed
71.
Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E, et al. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell. 2015;27(2):223–39.
CrossRefPubMedPubMedCentral
72.
Al-Asaaed S, Winquist E. Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer. Curr Oncol Rep. 2013;15:113–8.
CrossRefPubMed
73.
Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeyran P, De-Thonel A, et al. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene. 2010;29(13):1883–96 Epub 2010 Jan 18.
CrossRefPubMed
74.
Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer. PLoS One. 2014;9(7):e103680. eCollection 2014. PubMed PMID: 25072314.
75.
Stope MB, Weiss M, Preuss M, Streitbörger A, Ritter CA, Zimmermann U, et al. Immediate and transient phosphorylation of the heat shock protein 27 initiates chemoresistance in prostate cancer cells. Oncol Rep. 2014;32(6):2380–6 Epub 2014 Sep 17.
PubMed
76.
Marín-Aguilera M, Codony-Servat J, Reig Ò, Lozano JJ, Fernández PL, Pereira MV, et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther. 2014;13(5):1270–84 Epub 2014 Mar 21.
CrossRefPubMed
77.
Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai). 2010;42(6):363–9. Review. PubMed PMID: 20539944.
78.
Puhr M, Hoefer J, Schäfer G, Erb HH, Oh SJ, Klocker H, et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 2012;181(6):2188–201 Epub 2012 Oct 3.
CrossRefPubMed
79.
Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, et al. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer. 2014;110(10):2462–71 Epub 2014 Apr 8.
CrossRefPubMedPubMedCentral
80.
Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, Jost TR, et al. Tumor-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature. 2014;515(7525):134–7 Epub 2014 Aug 24.
CrossRefPubMed
81.
Terry S, Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol. 2014;4:60. eCollection 2014. Review. PubMed PMID: 24724054.
82.
Albrethsen J, Angeletti RH, Horwitz SB, Yang CP. Proteomics of cancer cell lines resistant to microtubule-stabilizing agents. Mol Cancer Ther. 2014;13(1):260–9 Epub 2013 Nov 19.
CrossRefPubMedPubMedCentral
83.
Ahmed AA, Mills AD, Ibrahim AE, Temple J, Blenkiron C, Vias M, et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 2007;12(6):514–27.
CrossRefPubMedPubMedCentral
84.
Fujita Y, Kojima T, Kawakami K, Mizutani K, Kato T, Deguchi T, et al. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells. Prostate. 2015;75(14):1568–78.
CrossRefPubMed
85.
Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate. 2010;70(14):1501–12.
CrossRefPubMed
86.
Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem. 2010;285(25):19076–84 Epub 2010 Apr 20.
CrossRefPubMedPubMedCentral
87.
Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N, et al. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene. 2011;30(43):4386–98 Epub 2011 May 9.
CrossRefPubMedPubMedCentral
88.
Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2011;71(3):326–31 Epub 2010 Sep 14.
CrossRefPubMed
89.
Fumoleau P, Trigo JM, Isambert N, Sémiond D, Gupta S, Campone M. Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumors. BMC Cancer. 2013;13:460. PubMed PMID: 24099585; PubMed Central PMCID: PMC3854123.
90.
Pivot X, Koralewski P, Hidalgo JL, Chan A, Gonçalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19(9):1547–52.
CrossRefPubMed
91.
Ferron GM, Dai Y, Semiond D. Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71(3):681–92.
CrossRefPubMedPubMedCentral
92.
Villanueva C, Awada A, Campone M, Machiels JP, Besse T, Magherini E, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer. 2011;47(7):1037–45.
CrossRefPubMed
94.
Ridoux L, Sémiond DR, Vincent C, Fontaine H, Mauriac C, Sanderink GJ, et al. A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Anticancer Drugs. 2015;26(3):350–8.
CrossRefPubMed
95.
Deeken JF, Löscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13(6):1663–74.
CrossRefPubMed
96.
Sémiond D, Sidhu SS, Bissery MC, Vrignaud P. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel. Cancer Chemother Pharmacol. 2013;72(3):515–28.
CrossRefPubMed
97.
Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol. 2014;66(3):459–65.
CrossRefPubMed
98.
Caffo O, Veccia A, Russo L, Galligioni E. Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario. Future Oncol. 2012;8(12):1585–95.
CrossRefPubMed
99.
De Placido S, Rescigno P, Federico P, Buonerba C, Bosso D, Puglia L, et al. Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. World J Clin Cases. 2014;2(6):228–31.
PubMedPubMedCentral
100.
Heidenreich A, Bracarda S, Mason M, Ozen H, Sengelov L, Van Oort I, et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur J Cancer. 2014;50(6):1090–9.
CrossRefPubMed
101.
Bahl A, Masson S, Malik Z, Birtle A, Sundar S, Jones R, et al. Final quality of life and safety data for patients with mCRPC treated with cabazitaxel in the UK early access programme (NCT01254279). BJU Int. 2015. PubMed PMID: 25639506.
102.
Wissing MD, van Oort IM, Gerritsen WR, van den Eertwegh AJ, Coenen JL, Bergman AM, et al. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands. Clin Genitourin Cancer. 2013;11(3):238–250.e1. PubMed PMID: 23659772.
103.
Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Müller SC, et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol. 2013;63(6):977–82.
CrossRefPubMed
104.
Castellano D, Antón Aparicio LM, Esteban E, Sánchez-Hernández A, Germà JR, Batista N, et al. Cabazitaxel EAP study. Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. Expert Opin Drug Saf. 2014;13(9):1165–73.
CrossRefPubMed
105.
Bracarda S, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R, et al. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol. 2014;10(6):975–83.
CrossRefPubMed
106.
Rasheed ZA, Rubin EH. Topoisomerase-interacting agents. In: DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2008. p. 438–447.
107.
Bahl A, Oudard S, Tombal B, Ozgüroglu M, Hansen S, Kocak I, et al. Impact of cabazitaxel on 2-year survival and palliation of tumor-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013;24(9):2402–8.
CrossRefPubMedPubMedCentral
109.
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–205.
CrossRefPubMed
110.
Omlin A, Sartor O, Rothermundt C, Cathomas R, De Bono JS, Shen L, et al. Analysis of side effect profile of Alopecia, nail changes, peripheral neuropathy, and dysgeusia in prostate cancer patients treated with docetaxel and cabazitaxel. Clin Genitourin Cancer. 2015;13(4):e205–8.
CrossRefPubMed
111.
Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013;105(22):1729–37.
CrossRefPubMedPubMedCentral
112.
Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015;26(4):750–5.
CrossRefPubMed
113.
Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, et al. Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol. PubMed PMID: 23718309.
114.
Oudard S, De Bono JS, Ozguroglu M, Hansen S, Machiels J, Kocak I, et al. Impact of cabazitaxel (Cbz) + prednisone (P; CbzP) on overall survival (OS) at 2 yrs and in patients (pts) with aggressive disease: post-hoc analyses of TROPIC trial [conference abstract]. Ann Oncol 2012;23:ix307.
115.
Scher HI, Kelly WM, Zhang ZF, Ouyang P, Sun M, Schwartz M, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst. 1999;91(3):244–51.
CrossRefPubMed
116.
Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, et al. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013;31(31):3944–50. PubMed PMID 24101043.
117.
Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, Eisenberger M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25(25):3965–70. Erratum in: J Clin Oncol. 2008;26(5):820. PubMed PMID: 17761981.
118.
Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006;98(8):516–21.
CrossRefPubMed
119.
Angelergues A, Maillet D, Fléchon A, Ozgüroglu M, Mercier F, Guillot A, et al. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. Eur J Cancer. 2014;50(9):1602–9.
CrossRefPubMed
120.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Prostate cancer clinical trials working group. design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26(7):1148–59.
CrossRefPubMedPubMedCentral
121.
Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, et al. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate. 2014;74(15):1544–50.
CrossRefPubMed
122.
Oudard S, Angelergues A. Prostate cancer: cabazitaxel–the taxane of choice in the new mCRPC landscape? Nat Rev Urol. 2014;11(7):370–2.
CrossRefPubMed
123.
Sella A, Sella T, Peer A, Berger R, Frank SJ, Gez E, et al. Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2014;12(6):428–32.
CrossRefPubMed
124.
Sonpavde G, Bhor M, Hennessy D, Bhowmik D, Shen L, Nicacio L, et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Cancer. 2015 [Epub ahead of print]. PubMed PMID: 25743206.
126.
Dragomir A, Dinea D, Vanhuyse M, Cury FL, Aprikian AG. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Serv Res. 2014;13(14):252.
CrossRef
127.
Vasani D, Josephson DY, Carmichael C, Sartor O, Pal SK. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. Maturitas. 2011;70(2):194–6.
CrossRefPubMedPubMedCentral
128.
Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of clinical oncology and cancer care Ontario clinical practice guideline. J Clin Oncol. 2014;32(30):3436–48.
CrossRefPubMed
129.
Kearns B, Jones ML, Stevenson M, Littlewood C. Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(6):479–88.
CrossRefPubMed